Relivar Journal References

CINV Literature

01. Chemothearpy-induced nausea and vomiting: clinician and patient perspectives.

Schwartzberg LS.

Journal of Supportive Oncology. (2007) 5 (No. 2, Suppl 1): 5-12.


Link to abstract

02. Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics.

Vanscoy GJ, Fortner B, Smith R, Weber R, Rihn TL.

Community Oncology. (2005) 2: 127-132.


Link to article

03. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada.

Lachaine J, Yelle L, Kaizer L, Dufour A, Hopkins S, Deuson R.

Supportive Cancer Therapy. (2005) 2(3): 181-187.


Link to article

04. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.

Slatkin NE.

The Journal of Supportive Oncology. (2007) 5 (5 suppl 3): 1-9.


Link to abstract

05. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.

de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J.

British Journal of Cancer. (1997) 76(8): 1055-61.


Link to abstract

06. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.

Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ.

BMJ. (2001) July 7; 323(7303): 16-21.


Link to article

07. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.

Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, Baranowski V.

Curr Med Res Opin. (2007) Mar; 23(3): 533-43.


Link to abstract

08. Antiemetic effect of delta-9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine.

Orr LE, McKernan JF.

Clin Pharmacol. (1981) Aug-Sep; 21(8-9 Suppl): 76S-80S.


Link to abstract

09. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.

Einhorn LH, Nagy C, Furnas B, Williams SD

J Clin Pharmacol. (1981) Aug-Sep; 21(8-9 Suppl): 64S-69S.


Link to abstract

10. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy.

Niiranen A, Mattson K.

American Journal of Clinical Oncology. (1985) Aug; 8(4): 336-40.


Link to abstract

Neuropathic Pain Literature

01. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man.

Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L.

Pharmacological Reviews. (1986) 38(1): 21-43.


Link to abstract

02. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomized controlled trial.

Berman JS, Symonds C, Birch R.

Pain. (2004) 112(3):299-306.


Link to abstract

03. Prevalence of chronic pain with neuropathic characteristics in the general population.

Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C.

Pain. (2008) 136 (3): 380-7.


Link to abstract

04. Peripheral neuropathy.

Cancerbackup. Macmillan Cancer Support. (11/2008).


Link to abstract

08. Fibromyalgia from the perspective of neuropathic pain.

Dworkin RH, Fields HL.

The Journal of Rheumatology. Supplement. (2005) 75: 1-5.


Link to abstract

09. Pharmacokinetics and Pharmacodynamics of Cannabinoids.

Grotenhermen F.

Clinical Pharmacokinetics.  (2003)  42(4): 327-360.


Link to abstract

05. Pipeline Insight: Neuropathic Pain. Emerging drugs fail to capitalize in lucrative market.

Datamonitor. (09/2007).


Link to purchase article

06. The endocannabinoid system and its therapeutic exploitation.

DiMarzo V, Bifulco M, DePetrocellis L.

Nature Reviews Drug Discovery. (2004) 3(9):771-84.


Link to abstract

07. Pharmacologic management of neuropathic pain: evidence-based recommendations.

Dworkin RH, O'Connor AB, Backonja M, et al.

Pain. (2007) 132 (3): 237-51.


Link to abstract

10. Information for Health Care Professionals (Revised).  Marihuana (Marijuana, Cannabis) Dried Plant for Administration by Ingestion or Other Means:  Psychoactive Agent.

Health Canada, Ottawa.  (2003).


Link to article

11. Metabolism and disposition of delta-9-tetrahydrocannabinol in man.

Lemberger L, Axelrod J, Kopin IJ.

Pharmacological Reviews. (1971) 23(4): 371-80.


Link to abstract

12. Sublingual administration of D9-tetrahydrocannabinol/h-cyclodextrin complex increases the bioavailability of D9-tetrahydrocannabinol in rabbits.

Mannila J, Jarvinen T, Jarvinen K, Tervonen J, Jarho P.

Life Sciences. (2006) 78(17):1911-4.


Link to abstract

13. Marijuana-produced changes in pain tolerance. Experienced and non-experienced subjects.

Milstein SL, MacCannell K, Karr G, Clark S.

International Pharmacopsychiatry. (1975) 10(3): 177-82.


Link to abstract

14. Analgesic effect of delta-9-tetrahydrocannabinol.

Noyes R Jr, Brunk SF, Baram DA, Canter A.

Journal of Clinical Pharmacology. (1975) 15(2-3): 139-43.


Link to abstract

15. The analgesic properties of delta-9-tetrahydrocannabinol and codeine.

Noyes R Jr, Brunk SF, Avery DA, Canter AC.

Clinical Pharmacology and Therapeutics. (1975) 18(1): 84-9.


Link to abstract

16. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.

Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK.

Clinical Pharmacology and Therapeutics. (1980) 28(3): 409-16.


Link to abstract

17. The endocannabinoid system as an emerging therapeutic target of pharmacotherapy.

Pacher P , Batkai S, Kunos G.

Pharmacological Reviews. (2006) 58(3): 389-462.


Link to article

18. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: D9-tetrahydrocannabinol, cannabidiol and D9-tetrahydrocannabivarin.

Pertwee RG.

British Journal of Pharmacology. (2008) 153(2): 199-215.


Link to article

19. Cannabinoids in the management of difficult to treat pain.

Russo E.

Therapeutics and Clinical Risk Management. (2008) 4(1): 245-59.


Link to article

20. Does the cannabinoid dronabinol reduce central pain in MS? Randomised double blind placebo controlled crossover trial.

Svendsen KB, Jensen TS, Bach FW.

British Medical Journal. (2004) 329(7460): 253.


Link to article

21. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey.

Torrance N, Smith BH, Bennett MI, Lee AJ.

The Journal of Pain (2006) 7 (4): 281-9.


Link to abstract

22. Painful peripheral neuropathies.

Vaillancourt PD, Langevin HM.

The Medical Clinics of North America. (1999) 83 (3): 627-42, vi.


Link to abstract

23. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.

Wade DT, Robson P, House H, Makela P, Aram J.

Clinical Rehabilitation. (2003) 17(1):21-29.


Link to abstract

24. Cannabinoids for the treatment of pain: an update on recent clinical trials.

Ware M, Beaulieu P.

Pain Research Management. (2005) 10A: 27.


Link to abstract

25. Cannabinoids in clinical practice.

Williamson EM, Evans FJ.

Drugs. (2000) 60: 1303.


Link to abstract
Horizonatal Rule
  About CynapsusLine SeperationRelivar ProductLine SeperationAPL-130277 ProductLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2010, Cynapsus Therapeutics Inc. All rights reserved.